O tratamento do COVID-19 na Nicarágua e o estranho “negacionismo terapêutico” da esquerda (Parte II de II)
A Nicarágua como um livro aberto para se entender a real natureza da narrativa da OMS.
Só pela contundência daqueles dados citados na primeira parte deste artigo, a esquerda deveria ter interesse em conhecer a experiência nicaraguense, levantar comitês científicos independentes, abrir o debate sobre as evidências a favor da ivermectina.
Dessa forma demonstraria sua preocupação com vidas da classe trabalhadora.
Mas ela fez o contrário, diametralmente o contrário.
No Brasil, por exemplo, o MST (movimento dos sem-terra) baniu a ivermectina dos seus acampamentos, ao menos é o que indica um vídeo “educativo” que o movimento divulgou na sua base (além dos artigos do seu jornal Brasil De Fato) sempre cancelando a ivermectina, como “remédio veterinário”. Para o MST, o pobre que aparecesse com virose respiratória deveria “ficar em casa” esperando piorar para cair na ventilação mecânica.
A disparidade é brutal: entre o exemplo da Nicarágua e o comportamento reacionário e obscurantista da esquerda, e não apenas a brasileira.
Também mundo afora, a esquerda censurou a ivermectina ou silenciou a respeito.
Praticou, sejamos diretos, censura política. Ao ponto de que não se pode falar a favor da ivermectina nos meios da esquerda. O cancelamento é imediato. Não se fala tampouco do exemplo da política de tratamento do COVID-19, na Nicarágua, com ivermectina. Tema tabu.
Seria inconveniente ideologicamente até pelo fato de que a vacinação na Nicarágua não foi obrigatória, mandatória, como exigiu a esquerda por aqui. E a ivermectina foi oferecida pelo governo de casa em casa, nas escolas, nos hospitais, por todo o país. Não se trata de “fake news” e sim realidade de um país que a esquerda admira, mas não, infelizmente, por isso, por ter sido vanguarda sanitária na pandemia.
Enquanto isso a esquerda vive a repetir o que os “fact checkers” (financiados pela Big Pharma), a Globo e a OMS determinam: “não há evidências” para validar a ivermectina. Dessa forma, opera como prolongamento ou pata esquerda do “consórcio de imprensa” do grande capital. E da anticiência, já que só reconhece ciência na OMS.
Portanto, vai ser no exemplo da Nicarágua que o oportunismo e o jogo politicamente desonesto da esquerda eclodirá de forma mais eloquente e insofismável.
Por que? Porque enquanto as forças de esquerda, os movimentos sociais que dizem defender o povo pobre, gritavam aos quatro ventos que “não há evidências” sobre a ivermectina – e a hidroxicloroquina – e jamais levantaram um só comitê independente para promover o debate científico necessário, a Nicarágua começou a usar a ivermectina e não mais deixou de usá-la.
Distribuindo de casa em casa. Não foi carne e unha com a Big Pharma como fez o conjunto da esquerda organizada. E foi bem sucedida.
E importante: a Nicarágua rejeitou algumas diretrizes da OMS: não fechou escolas, universidades, bares, não praticou qualquer lockdown nem distanciamento social. Permitiu aglomerações e eventos públicos todo o tempo e, portanto, que a vida seguisse. Não caiu no terror sanitário da agência imperialista do Tedros.
Não seria nem necessário acrescentar que a esquerda, que avalizou tudo que a OMS induziu os países a fazerem, fica muito mal nessa paisagem. Fechar escolas foi um contrassenso.
Em argumento do mais elementar bom senso, a conselheira de saúde do presidente Ortega declarou: se fechássemos escolas, as crianças sairiam perdendo, seu desenvolvimento seria comprometido e, nas escolas elas aprendem prevenção.
A pequena e grande economia não foi fechada na Nicarágua, continuou aberta na pandemia, sob a mais intensa chuva de críticas da OMS, dos USA, da burocracia médica amestrada.
E a esquerda aqui no Brasil (a esquerda pró-Nicarágua)?
Silêncio total, censurou ou cancelou o tema Nicarágua-na-pandemia. Nenhum jornal da esquerda se ocupou disso. Um silêncio envergonhado que revela sua subserviência à OMS/Big Pharma. Ou desinteresse sobre o tema, sobre a ciência na pandemia.
Evitou o contraditório, aquilo que contrariava a narrativa imperialista da OMS, rejeitou qualquer debate a respeito. Enquanto continuava cancelando a ivermectina e apoiando todo lockdown e tudo que a OMS quis.
Posso estar enganada, mas tudo indica que essa é uma das maiores e inegáveis provas da capitulação da esquerda à política sanitária da OMS – eivada de interesses imperialistas – e que todo o tempo vetou tratamento do coronavírus com ivermectina ou hidroxicloroquina. Sem debate (quando, na verdade, desde antes, os dois medicamentos constavam da lista de drogas essenciais da própria OMS).
Enquanto isso, a Nicarágua usava a ivermectina e ainda usa, oficialmente, como política de Estado, e Cuba também usa parcialmente a ivermectina (embora tenha sido muito mais fiel à política sanitária da OMS). Sem falarmos em outros países da America do Sul e do mundo, embora de maneira menos oficial, mais disfarçadamente.
Na Argentina a ivermectina foi usada em ao menos cinco províncias (Missiones, Corrientes [49], La Pampa, Salta [43], Tucuman).
Para quem ainda duvide do fator ivermectina na Nicarágua, da sua adoção oficial pelo governo nos hospitais e de casa em casa, pode conferir a entrevista recente da conselheira de Saúde do presidente da Nicarágua, a Dra Sonia Castro (a partir do minuto 12 do vídeo abaixo). Lá fica claro que aquele governo não pesou duas vezes em fazer pesquisa séria e passar a usar esse medicamento, prontamente incorporado nos protocolos oficiais de tratamento da virose.
Enquanto isso, a esquerda, abduzida pela OMS, virou força tarefa desta agência imperialista, repetindo mundo afora que “não há evidências” e que “esperem as vacinas” e, caso adoeçam, procurem o ventilador mecânico (de altíssima letalidade). E nem uma palavra sobre a experiência nicaraguense.
Agora reflitamos: esse fato, do uso massivo da ivermectina pelo governo nicaraguense, ícone de quase toda a esquerda, no tratamento dessa virose, em que localização deixa a esquerda que operou todo o tempo como militante do “negacionismo terapêutico”?
A esquerda esgrimiu ideologia, atacou qualquer médico que defendesse a ivermectina como charlatão, “contrário à ciência”, “espalhador de desinformação” e até “bolsonarista”. Mas vamos combinar: contra fatos de que serve essa ideologia da esquerda atrelada à narrativa da OMS? De que serve censurar se os fatos estão disponíveis para quem quiser buscá-los.
Pensemos: a ivermectina é boa para o povo da Nicarágua, mas para os trabalhadores do mundo não. Lógica de uma esquerda sem lógica.
Então o medicamento funciona no povo nicaraguense, cura pessoas na Nicarágua, mas não serve para nenhum outro povo. Na Nicarágua, o coronavírus é sensível à ivermectina, mas aqui e no resto do mundo não. Zero dialética.
Aqui, ivermectina é “desinformação” e “sem evidências”. Na Nicarágua, é informação com evidências; e é política de Estado.
Quando a esquerda censura e cancela a ivermectina, ela está “seguindo a ciência”, mas então, temos que imaginar que os hospitais e médicos da Nicarágua estão “contra a ciência”. Qual o cabimento desse tipo de antidialética?
Não tem cabimento, mas teve efeito: se na Nicarágua ivermectina funciona e salvou e salva vidas, é lícito concluir que a esquerda organizada local – toda ela - contribuiu ativamente para que vidas se perdessem no Brasil. Vidas de trabalhadores que a esquerda diz defender.
A entrevista da ministra nicaraguense, por sua vez, coloca-se por fora e contra a narrativa medicamentosa e sanitária da OMS. (Na nossa análise, nesta nota, não pretendemos examinar a política do governo nicaraguense em geral).
Esquizofrenia pura. Abandono da posição de classe e do seu tradicional antiimperialismo.
Tal localização da esquerda pode muito bem ser consequência de determinações muito mais profundas, históricas, que remetem para uma adaptação dessas correntes autoproclamadas marxistas ao inimigo de classe, às políticas da burguesia imperialista.
Uma adaptação já vivida há mais de cem anos atrás, quando a social democracia – a esquerda então hegemônica na Europa – se alinhou com o imperialismo nacional na grande carnificina da I Guerra. Virou esquerda adaptada ao militarismo. Afundou. Deu passagem a outra esquerda.
Só que, hoje, tal abdução pela política imperialista, pela narrativa pandêmica do imperialismo/OMS chega - diante do exemplo nicaraguense no sentido contrário -, às raias do absurdo.
É como se a esquerda, para fazer valer suas teses – defesa da OMS com seus lockdowns e seu negacionismo terapêutico – tivesse que negar a realidade. O que soa surreal. Esquerda agindo como papagaio da OMS. Atelada à escória do mundo da BigPharma, Gates, Tedros et caterva.
Ora, censurar e negar tratamento – o mesmo que a Nicarágua oferece ao seu povo – aos trabalhadores do mundo inteiro é a mais cabal demonstração de que a esquerda organizada ficou cega, ideológica e cientificamente cega, tal o seu grau de adaptação política ao imperialismo e seu terror sanitário diante de um vírus de taxa de letalidade de 0,6%, comparável à da influenza, atacando principalmente as pessoas fragilizadas por doenças e idade.
A esquerda revelou – além do seu autoritarismo - abandono da mais elementar lógica científica e do próprio senso comum e, em consequência, tornou-se cúmplice de crimes - uma vez que há tratamento, é barato e está disponível - só para ficar bem com a OMS, “seguir a ciência” da OMS.
Sem a superação dessa esquerda – que nega tratamento para fazer a apologia da injeção experimental, que é o provável objetivo comercial da Big Pharma nessa pandemia – está aberto o caminho para a barbárie. No que depender dela, seremos reféns do imperialismo e sua narrativa de “emergências”. E da barbárie de eventualmente morrer de uma doença que TEM tratamento, como mostrou a Nicarágua.
Por outro lado, a grande verdade é que os trabalhadores estarão órfãos diante da próxima agressão imperialista, seja ela guerra ou emergências de todo tipo, invariavelmente funcionais para a crise econômica do sistema (emergência do tipo sanitária, climática, cibernética ou o que parecer mais adequado para os políticos manterem o sistema de pé).
Constitui o mais grosseiro oportunismo negar tratamento com ivermectina no mundo inteiro e, ao mesmo tempo, ignorar que na Nicarágua vidas são salvas pelo recurso ao tratamento conhecido, não patenteável e barato para essa virose respiratória (ivermectina, vitamina D, zinco, azitromicina e outros).
É como se a esquerda, em sua adaptação ao sistema capitalista, tivesse perdido sua razão de existir, como força independente, de classe. |Tendo que dar lugar a uma força politicamente consciente e de classe, em algum momento.
Ziau jan 2023.
Vídeo da conselheira de Saúde do governo nicaraguense, Dra Sonia Castro:
__ __ __ __
NOTAS
(1) https://www.vozdeamerica.com/a/nicaragua-autoridades-polemica-droga-covid19/6219503.html
(3) Ivermectina y colchicina no funciona para la covid-19 y la distribuyen en Nicaragua, denuncia Leonel Argüello. 100% Noticias, 09/2021. https://100noticias.com.ni/nacionales/109932-advierten-ivermectina-distribuida-nicaragua-covid/?mobile
(4) SHIFFMAN, G, 2021. https://www.laprensani.com/2021/01/25/nacionales/2776166-minsa-acude-a-la-ivermectina-para-tratar-a-pacientes-con-covid-19
(5) The Conversation, 2021. https://www.gavi.org/vaccineswork/ivermectin-why-potential-covid-treatment-isnt-recommended-use
(6) Priorities for dealing with Nicaragua’s new COVID-19 phase. Nov 2020. Envío Digital. https://www.envio.org.ni/articulo/5847
(7) REDACCIÓN CONFIDENTIAL, 2021. Publicado em outubro de 2021. NSA invests $763,000 in questionable “Covid medicines” - https://www.confidencial.digital/english/minsa-invests-763000-in-questionable-covid-medicines/
Bibliografia adicional:
1. “7 Facts You Probably Don’t Know About Big Pharma.” (July 2015). The Motley Fool. Accessed July 25, 2016.
2. “Pharmaceutical Research And Development: What Do We Get For All That Money?” (2012). The BMJ. Accessed July 26, 2016.
3. “Sick of Pharmaceutical Ads? Here’s Why They Won’t Go Away.” (October 2011). Io9. Accessed July 25, 2016.
4. “Medical Money: See What Drug and Device Makers Paid Doctors.” (October 2014). Wall Street Journal. Accessed July 26, 2016.
5. “Pfizer Pays $2.3 Billion to Settle Marketing Case.” (September 2009). The New York Times. Accessed July 25, 2016.
6. “Big Pharma is America’s New Mafia.” (February 2015). The Daily Beast. Accessed July 26, 2016.
7. “Big Pharma Pockets $711 Billion in Profits by Robbing Seniors, Taxpayers.” (June 2013). The Huffington Post. Accessed October 20, 2015.
8. “Updated: Astrazeneca Slaps Down Pfizer’s ‘Final’ $119B Takeover Bid.” (May 2014). FierceBiotech. Accessed July 26, 2016.
9. “Do Drug Companies Make Drugs, or Money?” (June 2014). The New York Times. Accessed July 26, 2016,
10. “The Truth About Generic Vs. Brand-Name Medications.” (February 2015). The Huffington Post. Accessed July 27, 2016.
11. “Watch John Oliver Skewer the Cozy Relationship Between Doctors and Pharmaceutical Companies.” (February 2015). Business Insider. Accessed July 26, 2016.
12. “How to Win Doctors and Influence Prescriptions.” (October 2010). NPR. Accessed July 26, 2016.
13. “Big Pharma’s Big Fines.” (February 2014). Pro Publica. Accessed July 27, 2016.
14. Angell M. Is academic medicine for sale? (editorial) N Engl J Med 2000;342(20):1516-8. (PubMed)
15. IVERMECTINA. Redação Médicos Pela Vida (MPV). COVID-19: estudo ´padrão ouro´ comprova eficácia da ivermectina. Disponível em: https://medicospelavidacovid19.com.br/noticias/covid-19-estudo-padrao-ouro-comprova-eficacia-da-ivermectina/ Reflexão ao final do artigo dos MPV: São agora 17 estudos. Vão falar que esse, que apenas confirma os anteriores, não comprova nada e vão fingir demência sobre o conjunto de evidências de todos os outros? Só há um único recurso para vocês, mas só se forem falar apenas desse estudo, da Bulgária. Ele ainda não é revisado por pares. Mas entre os 16 anteriores, a imensa maioria é. Este só confirmou. Vão se agarrar nisso como uma bóia de salvação? Se forem para esse lado, afirmando que falta revisão por pares para dizer que não comprova (resultados assim nunca mudam), vão jogar nas manchetes como “eficaz” após a revisão ou já foram longe demais, passando do ponto de não retorno? Quantos estudos unânimes precisam mais para falarem um “Desculpem. Erramos. Funciona sim e sempre funcionou”? Uns trinta? Cinquenta? Cem? Vão mandar gente para o cemitério por teimosia até quando? Se este fosse o primeiro, até nós, do MPV – Médicos Pela Vida, aguardaríamos a revisão. Mas como confirmou o que a gente já sabe, não é necessário. Leia mais: Ivermectina em Itajaí e também COVID-19: Jornal da USP mente e distorce a ciência para atacar a ivermectina. Leia a análise completa
16. AFSAR et al., SSRN (Preprint) Ivermectin Use Associated with Reduced Duration of COVID-19 Febrile Illness in a Community Setting Small 95 patient study in Pakistan adding ivermectin to standard of care (HCQ+AZ) for outpatients with mild/moderate suspected COVID-19, showing faster resolution of fever with ivermectin. https://c19hcq.com/afsar.html
17. AHMED et al., (Peer Reviewed) A five day course of ivermectin for the treatment of COVID-19 may reduce the duration of illness” - There were no severe adverse drug events recorded in the study. A 5-day course of ivermectin was found to be safe and effective in treating adult patients with mild COVID-19. Larger trials will be needed to confirm these preliminary findings”.
ALAM et al., 2020.A Case Series of 100 COVID-19 Positive Patients Treated with Combination of Ivermectin and Doxycycline International Journal of Infectious Diseases, doi:10.1016/j.ijid.2020.11.191. Journal of Bangladesh College of Physicians and Surgeons, doi:10.3329/jbcps.v38i0.47512 (Peer Reviewed) “All patients tested negative and their symptoms improved within 72 hours. There were no noticeable side effects. Conclusion: Combination of Ivermectin and doxycycline was found to be very effective in viral clearance in mild and moderately sick COVID-19 patients. Medical societies and institutions should undertake larger multi center studies to validate and recommend this combination therapy to include in national guidelines”. Case study of 100 patients treated with ivermectin and doxycycline, with no ICU admission, deaths, or serious side effects reported. https://www.researchgate.net/publication/343305357_A_Case_Series_of_100_COVID-19_Positive_Patients_Treated_with_Combination_of_Ivermectin_and_Doxycycline
18. ALONSO et al., (Preprint) https://c19ivermectin.com/
Observational study in Argentina showing significantly lower mortality in the 60 days after adopting ivermectin compared to the 60 days before,
19 ARÉVALO et al.,2020. Ivermectin reduces coronavirus infection in vivo: a mouse experimental model bioRxiv, doi:10.1101/2020.11.02.363242 (Preprint) animal study - https://pesquisa.bvsalud.org/portal/resource/pt/ppbiorxiv-363242
20.BARROWS, N. J., Campos, R. K., et al. (2016). A Screen of FDA-Approved Drugs for Inhibitors of Zika Virus Infection. Cell host & microbe, 20(2), 259–270.
https://doi.org/10.1016/j.chom.2016.07.004
21. BEHERA et al.2020. Role of ivermectin in the prevention of COVID-19 infection among healthcare workers in India: a matched case-control study , medRxiv, doi:10.1101/2020.10.29.20222661v1 (Preprint) cases, ? https://www.medrxiv.org/content/10.1101/2020.10.29.20222661v1 Retrospective prophylaxis study for HCQ, ivermectin, and vitamin C with 372 healthcare workers, showing lower COVID-19 incidence for all treatments, with statistical significance reached for ivermectin. HCQ OR 0.56, p = 0.29 Ivermectin O.. - “Conclusion - Two-dose ivermectin prophylaxis at a dose of 300 μg/kg with a gap of 72 hours was associated 73% reduction of COVID-19 infection among healthcare workers for the following one-month. Further research is required before its large scale use”.
22. BERNIGAUD et al., Annals of Dermatology and Venereology, doi:10.1016/j.annder.2020.09.231 (Peer Reviewed) Ivermectin benefit: from scabies to COVID-19, an example of serendipity https://c19ivermectin.com/bernigaud.html
23. CADEGIANI et al., medRxiv, 2020. Therapy with Azithromycin Plus Nitazoxanide, Ivermectin or Hydroxychloroquine in Outpatient Settings Significantly Reduced Symptoms Compared to Known Outcomes in Untreated Patients doi:10.1101/2020.10.31.20223883 (Preprint) death, ? Early COVID-19 https://www.medrxiv.org/content/10.1101/2020.10.31.20223883v1 Comparison of HCQ, nitazoxanide, and ivermectin showing similar effectiveness for overall clinical outcomes in COVID-19 when used before seven days of symptoms, and overwhelmingly superior compared to the untreated COVID-19 population, ev.. ” Early pharmacological approaches including azithromycin in combination with any of the options between nitazoxanide, ivermectin or optionally hydroxychloroquine should be considered for those diagnosed with COVID-19 presenting less than seven days of symptoms. Of the three drugs, we opted for nitazoxanide, due to more extensive demonstration of in vitro and in vivo antiviral activity, proven efficacy against other viruses in humans, and steadier safety profile”.
24.CHANGJIELv et al., 2018. Ivermectin inhibits DNA polymerase UL42 of pseudorabies virus entrance into the nucleus and proliferation of the virus in vitro and vivo, Antiviral Research, Volume 159, November 2018, Pages 55-2. https://doi.org/10.1016/j.antiviral.2018.09.010
25. CALY et al., 2020.The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro, Antiviral Research, Vol. 178, June 2020, 104787. https://doi.org/10.1016/j.antiviral.2020.104787
26. CHAMIE, J. (News) The effect of using ivermectin to control COVID-19 in Chiapas https://c19ivermectin.com/chamie.html After starting to distribute ivermectin in drug kits in July, the Mexican state of Chiapas has seen a dramatic divergence from other states with much lower mortality (1, 2).
27. CHANG et al., ResearchGate (Preprint) Post-acute or prolonged COVID-19: ivermectin treatment for patients with persistent symptoms or post-acute symptoms Report on 33 patients with persistent or post-acute symptoms treated with ivermectin, showing a high rate of clinical improvement. “CONCLUSION: The result of the present study demonstrates that clinical improvement is observed in high percentage of patients with Persistent or Post-Acute Symptoms of COVID-19 who are treated with Ivermectin. Given the high number of patients with Persistent Symptoms and a favorable clinical response seen after receiving this specific treatment, we recommend that additional clinical studies be carried out on the use of Ivermectin and other drugs to reduce and eliminate the viral load in these cases”. https://www.researchgate.net/publication/344318845
28. CHOWDHURY et al., A Randomized Trial of Ivermectin-Doxycycline and Hydroxychloroquine-Azithromycin therapy on COVID19 patients Research Square, doi:10.21203/rs.3.rs-38896/v1 (Preprint) - “Conclusion The Ivermectin-Doxycycline combination showed a trend toward superiority to the Hydroxychloroquine-Azithromycin combination therapy in the case of patients with mild to moderate COVID19 disease, though the difference in time to becoming symptom-free and the difference in time to negative PCR was not statistically significant”. https://www.researchsquare.com/article/rs-38896/v1
29. COVID-19 - Inclusión de la ivermectina en la primera línea de acción terapéutica para
COVID-19. Se reporta una muy significativa disminución de la Tasa de Letalidad con su uso. http://dx.doi.org/10.13140/RG.2.2.34689.48482/4
30. CRUMP, A. Ivermectin: enigmatic multifaceted ‘wonder’ drug continues to surprise and exceed expectations. J Antibiot. 2017;70:495–505. https://dx.doi.org/10.1038 /ja.2017.11
31. CRUMP, A., & Ōmura, S. (2011). Ivermectin, ’wonder drug’ from Japan: the human use perspective. Proceedings of the Japan Academy. Series B, Physical and biological sciences, 87(2), 13–28. https://doi.org/10.2183/pjab.87.13
32. DEEP STATE. https://en.wikipedia.org/wiki/Deep_state_in_the_United_States
33. DEEP STATE. https://theprint.in/world/deep-state-fda-is-taking-a-beating-as-review-of-covid-vaccine-approaches/491554/
34. ELGAZZAR et al., Efficacy and Safety of Ivermectin for Treatment and prophylaxis of COVID-19 Pandemic Research Square, (Preprint) https://www.researchsquare.com/article/rs-100956/v2 ” Conclusion: Addition of Ivermectin to standard care is very effective drug for treatment of COVID-19 patients with significant reduction in mortality compared to Hydroxychloroquine plus standard treatment only. Early use of Ivermectin is very useful for controlling COVID 19 infections; prophylaxis and improving cytokines storm”.
35. FRANCÉS-MONERRIS et al., ) Has Ivermectin Virus-Directed Effects against SARS-CoV-2? Rationalizing the Action of a Potential Multitarget Antiviral ChemRxiv, doi:10.26434/chemrxiv.12782258.v1 (Preprint) (Theory Agent https://chemrxiv.org/articles/preprint/Has_Ivermectin_Virus-Directed_Effects_against_SARS-CoV-2_Rationalizing_the_Action_of_a_Potential_Multitarget_Antiviral_Agent/12782258/1 “Hence, the wide spectrum of actions involving i) the interference with cell infection, ii) the inhibition of viral replication, and iii) elusion of the host immune system, could point to an unprecedented synergy between host- and virus-directed effects explaining the high anti-SARS-CoV-2 activity observed for this compound”.
36. GEARY, T. G. 2005. Ivermectin 20 years on: maturation of a wonder drug. Trends in parasitology, 21(11), 530–532. https://doi.org/10.1016/j.pt.2005.08.014
37. GORIAL et al.,2020. Effectiveness of Ivermectin as add-on Therapy in COVID-19 Management (medRxiv, doi:10.1101/2020.07.07.20145979 (Preprint) death, Pilot Trial) - “ConclusionsAdd-on use of IVM to HCQ and AZT had better effectiveness, shorter hospital stay, and relatively safe compared with controls. however, a larger prospective study with longer follow up may be needed to validate these results”. https://pesquisa.bvsalud.org/portal/resource/pt/ppmedrxiv-20145979
38. GUZZO, CA, Furtek CI, et al. 2020. Safety, tolerability, and pharmacokinetics of escalating high doses of ivermectin in healthy adult subjects. J Clin Pharmacol. 2002 Oct;42(10):1122-33. doi: 10.1177/009127002401382731. PMID: 12362927.
39. 40. HARRIS G. 2003. A drug giant thinks it can grow still bigger. New York Times 2003 Jun 19; Sect C:1(col 2).
40. HASHIM et al., 2020. Controlled randomized clinical trial on using Ivermectin with Doxycycline for treating COVID-19 patients in Baghdad, medRxiv, doi:10.1101/2020.10.26.20219345 (Preprint) death, ? Iraq https://www.medrxiv.org/content/10.1101/2020.10.26.20219345v1 ” Conclusions Ivermectin with doxycycline reduced the time to recovery and the percentage of patients who progress to more advanced stage of disease; in addition, Ivermectin with doxycycline reduced mortality rate in severe patients from 22.72% to 0%; however, 18.2% of critically ill patients died with Ivermectin and doxycycline therapy. Taken together, the earlier administered Ivermectin with doxycycline, the higher rate of successful therapy
41. HEIDARY, Fatemeh; Gharebaghi, Reza 2020-09). Ivermectin: a systematic review from antiviral effects to COVID-19 complementary regimen. The Journal of Antibiotics, 73 (9): 593-602. http://www.nature.com/articles/s41429-020-0336-z
42. IVERMECTINA . ND Notícias. Médico do Paraná. Covid-19: Especialista defende uso de medicamentos para tratamento precoce - 5 de mar. de 2021 – Programa ND Notícias -
43. IVERMECTINA. "Evaluación del efecto antiviral del fármaco ivermectina contra SARS-CoV-2” https://www.argentina.gob.ar/noticias/un-estudio-demuestra-la-respuesta-antiviral-de-la-ivermectina-en-pacientes-con-covid-19 Instituto de Investigaciones de Enfermedades Tropicales de la Sede regional Orán de la Universidad Nacional de Salta (UNSa), Laboratorio de Farmacología del Centro de Investigación Veterinaria de Tandil (CIVETAN), Universidad Nacional de Quilmes; del Hospital Juan P. Garrahan, y del Centro de Educación Médica e Investigaciones Clínicas “Norberto Quirno” (CEMIC), e integrantes del Laboratorio ELEA-Phoenix,
44. CHANG et al. COVID-19: Post-exposure prophylaxis with ivermectin in contacts. At Homes, Places of Work, Nursing Homes, Prisons, and Others ResearchGate, doi:10.13140/RG.2.2.34561.48483/2 (Preprint) - “The inclusion of Acetylsalicylic Acid (ASA) or Aspirin in the PEP Schedule should be considered for men over 55 years of age and in persons with Increased Risk of developing severe illness. Recommended dose is 1 tablet of 100 mg after lunch for 6 to 10 days. Contacts should remain under observation in case they begin to show characteristic symptoms of COVID-19, in which case they should move to therapeutic doses of Ivermectin”.https://www.researchgate.net/publication/344781515_COVID-19_POST-EXPOSURE_PROPHYLAXIS_WITH_IVERMECTIN_IN_CONTACTS_At_Homes_Places_of_Work_Nursing_Homes_Prisons_and_Others
45. IVERMECTINA. Bangladesh: ivermectin shows promise in treating vírus - https://www.aa.com.tr/en/asia-pacific/bangladesh-ivermectin-shows-promise-in-treating-virus/2068885
46. IVERMECTINA. Belgian Virologist Proposes a Plan to Eradicate COVID-19 in 6 Weeks Using Ivermectin - Fev 2021 https://trialsitenews.com/belgian-virologist-proposes-a-plan-to-eradicate-covid-19-in-6-weeks-using-ivermectin/ “Referencing the meta-analysis from Dr. Tess Lawrie in the UK, the Belgian virologist shares that based on 15 randomized controlled trials and observational controlled trials, the ivermectin treatment reduces deaths by an average of 83% (95% Cl 65%-92%). He shares that based on the Dr. Lawrie meta-analysis, the drug also reduces the risk of deterioration by 53% (95% Cl 23%-71). Furthermore, Wathelet cites Lawrie that the drug used as prophylaxis given to health care workers or relatives can reduce the risk of infection by 88% (95% Cl 82%-92%). He aligns with America-based Front Line COVID-19 Critical Care Alliance (FLCCC) “.
47. IVERMECTINA. Effects of Ivermectin-azithromycin-cholecalciferol combined therapy on COVID-19 infected patients: A proof of concept study https://www.alliedacademies.org/abstract/effects-of-ivermectinazithromycincholecalciferol-combined-therapy-on-covid19-infected-patients-a-proof-of-concept-study-14435.html
Small study with 28 patients treated with ivermectin + AZ + cholecalciferol and 7 control patients. All treated patients were PCR- at day 10 while all control patients remained PCR+. “This study found that the combination treatment might mitigate disease progression without significant adverse effects. Further studies are needed in order to extrapolate these findings to moderate and severe COVID-19”.
48. IVERMECTINA. http://conselho.saude.gov.br/ultimas-noticias-cns/1570-cns-pede-que-ministerio-da-saude-retire-publicacoes-sobre-tratamento-precoce-para-covid-19 Em janeiro de 2021 o Conselho Nacional de Saúde pede que Ministério da Saúde elimine publicações sobre tratamento precoce da COV-19. (http://conselho.saude.gov.br/ultimas-noticias-cns/1570-cns-pede-que-ministerio-da-saude-retire-publicacoes-sobre-tratamento-precoce-para-covid-19). “O presidente do CNS, Fernando Pigatto, destaca que desde o início da pandemia o Conselho tem se posicionado contrário à indicação de qualquer medicamento para tratamento da Covid-19 sem eficácia comprovada. “O que foi reafirmado pela Anvisa, em coletiva no último domingo (17/1), durante o anúncio das vacinas. Portanto, estamos orientando por ofício que sejam revogadas toda e qualquer publicação do MS que orientem o tratamento precoce”, destaca Pigatto”.
49. IVERMECTINA. http://pharmabaires.com/1767-salta-y-corrientes-adoptan-ivermectina-en-sus-protocolos-covid.html
51. IVERMECTINA. http://www.cofen.gov.br/anvisa-esclarece-que-ivermectina-nao-e-indicada-contra-covid-19_81155.html
52. IVERMECTINA. https://andina.pe/agencia/noticia-coronavirus-arequipa-entrega-primer-lote-ivermectina-producido-la-region-802855.aspx
53. IVERMECTINA. https://canaltech.com.br/saude/agencia-federal-dos-eua-alerta-para-riscos-do-uso-de-ivermectina-contra-covid-19-180381/ em 11-3-2021
54. IVERMECTINA. https://megalabs.global/peru-comienza-la-produccion-masiva-de-ivermectina/
55. IVERMECTINA. https://pesquisa.bvsalud.org/global-literature-on-novel-coronavirus-2019-ncov/resource/en/covidwho-896543 100 patient prospective trial of ivermectin + doxycycline showing reduced time to symptom resolution and shorter hospital stay with treatment. “Our study supports the benefits of utilization of combination of Doxycycline and Ivermectin in mild to moderate COVID-19 infection in terms of early recovery based on the time for symptom resolution and the mean duration of hospital stay”
56. IVERMECTINA. https://www.argentina.gob.ar/noticias/un-estudio-demuestra-la-respuesta-antiviral-de-la-ivermectina-en-pacientes-con-covid-19
57. IVERMECTINA. https://www.cardioinfantil.org/recados-unidad-sintesis-transferencia/ivermectina-y-covid-19/
62. IVERMECTINA. https://www.las2orillas.co/ivermectina-la-formula-contra-el-covid-que-en-cali-esta-funcionado/
63. IVERMECTINA. https://www.semana.com/vida-moderna/salud/articulo/ivermectina--precio-beneficios-y-otros-datos-del-farmaco--cali-noticias-hoy/685291/
65. IVERMECTINA. https://www.trialsitenews.com/medincell-continues-its-investigational-pursuit-of-ivermectin-targeting-covid-19-patients/
66. IVERMECTINA. https://www.trialsitenews.com/university-of-kentucky-embraces-ivermectin-other-experimental-medications-in-pick-the-winner-covid-19-trial/
67. IVERMECTINA. Ivermectin as a Broad-Spectrum Host-Directed Antiviral: The Real Deal? - Review of ivermectin as a host-directed broad-spectrum antiviral agent for a range of viruses, including SARS-CoV-2. Cell culture experiments show robust antiviral action towards HIV-1, dengue virus (DENV), Zika virus, West Nile virus, V.. https://pubmed.ncbi.nlm.nih.gov/32942671/ - “This mini-review discusses the case for ivermectin as a host-directed broad-spectrum antiviral agent for a range of viruses, including SARS-CoV-2”. -
68. IVERMECTINA. Ivermectin medicine to be used for Covid-19 treatment in Uttar Pradesh
https://www.knocksense.com/lucknow/ivermectin-medicine-to-be-used-for-covid-19-treatment-in-uttar-pradesh
69. IVERMECTINA. Ivermectin to prevent hospitalizations in patients with COVID-19 (IVERCOR-COVID19): a structured summary of a study protocol for a randomized controlled Trial https://trialsjournal.biomedcentral.com/articles/10.1186/s13063-020-04813-1
70. IVERMECTINA. Un estudio demuestra la respuesta antiviral de la ivermectina en pacientes con COVID-19 - https://www.argentina.gob.ar/noticias/un-estudio-demuestra-la-respuesta-antiviral-de-la-ivermectina-en-pacientes-con-covid-19
71.IVERMECTINA.https://www.reddit.com/r/COVID19/comments/hk75iz/ivermectin_for_covid19_treatment_clinical/
72.IVERMECTINA.https://www.reddit.com/r/ivermectin/comments/l7iwld/ivermectin_to_save_belgium_belgium_20201222/
73.IVERMECTINAhttps://www.reddit.com/r/ivermectin/comments/hjxchk/new_preprint_dramatically_better_response_for_ivm/
74..JANS, D. A., & Wagstaff, K. M. 2020. The broad spectrum host-directed agent ivermectin as an antiviral for SARS-CoV-2 ?. Biochemical and biophysical research communications, S0006-291X(20)31959-8. Advance online publication. https://doi.org/10.1016/j.bbrc.2020.10.042
75. KHAN et al., 2020. Ivermectin treatment may improve the prognosis of patients with COVID-19 - Archivos de Bronconeumología, doi:10.1016/j.arbres.2020.08.007 (Letter) https://www.archbronconeumol.org/es-ivermectin-treatment-may-improve-prognosis-articulo-S030028962030288X - “Therefore, given the urgent need to manage the COVID-19 patients with a safe, cheap and widely available drug, the present findings suggest that ivermectin can be considered as a first-line treatment for containing SARS-CoV-2 to prevent severe irreversible respiratory complications and community transmission. A multicenter, double-blind, drug-controlled study will strengthen our findings”.
76. LEHRER et al., Ivermectin Docks to the SARS-CoV-2 Spike Receptor-binding Domain Attached to ACE2 In Vivo, 34:5, 3023-3026, doi:10.21873/invivo.12134 (Theory) https://www.x-mol.com/paper/1302073874220027904?recommendPaper=5812856 In silico analysis showing ivermectin docking which may interfere with the attachment of the spike to the human cell membrane.
77. LEON CALY, Julian D Druce et al - The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro – “We report here that Ivermectin, an FDA-approved anti-parasitic previously shown to have broad-spectrum anti-viral activity in vitro, is an inhibitor of the causative virus (SARS-CoV-2), with a single addition to Vero-hSLAM cells 2 h post infection with SARS-CoV-2 able to effect 5000-fold reduction in viral RNA at 48 h. Ivermectin therefore warrants further investigation for possible benefits in humans”.
“ - https://www.sciencedirect.com/science/article/pii/S0166354220302011
78. MAHMUD et al., Clinical Trial of Ivermectin Plus Doxycycline for the Treatment of Confirmed Covid-19 Infection Clinical Trial Results, NCT04523831 (Preprint) https://clinicaltrials.gov/ct2/show/results/NCT04523831?view=results RCT for ivermectin+doxycycline showing improvements in mortality, recovery, progression, and virological cure. There is no paper yet, results are reported on clinicaltrials.gov. 183 treatment and 180 control patients.
79. MOMEKOV et al., Ivermectin as a potential COVID-19 treatment from the pharmacokinetic point of view: antiviral levels are not likely attainable with known dosing regimens, Journal Biotechnology & Biotechnological Equipment, 05 Jun 2020.
80. NGUYEN et al. Therapeutic use of ivermectin against nuclear viruses in all animals: Ivermectin blocks the nuclear location signal of parvoviruses, Aquaculture, Vol. 420/1, 15/01/14, Pg. 288-294. https://doi.org/10.1016/j.aquaculture.2013.11.022
81. NIAEE et al., Analysis of COVID-19 cases vs. widespread prophylactic use of ivermectin for parasitic infections showing significantly lower incidence of COVID-19 Research Square, doi:10.21203/rs.3.rs-109670/v1 (Preprint) cases. https://www.researchsquare.com/article/rs-109670/v1 “ Ivermectin as an adjunct reduced the rate of mortality, low O2 duration, and duration of hospitalization in adult COVID 19 patients. The improvement of other clinical parameters showed that the ivermectin, with a wide margin of safety, had a high therapeutic effect on COVID-19”.
82. SPOORTHI et al., Utility of Ivermectin and Doxycycline combination for the treatment of SARSCoV- IAIM, 2020, 7:10, 177-182 (Peer Reviewed)
83. PATRI et al.,2020. Hydroxychloroquine and ivermectin: A synergistic combination for COVID-19 chemoprophylaxis and treatment?, Journal of the American Academy of Dermatology, Volume 82, ISSUE 6, e221, June 01, 2020. https://doi.org/10.1016/j.jaad.2020.04.017
84. PEÑA-SILVA, R. et al., 2020. Pharmacokinetic considerations on the repurposing of ivermectin for treatment of COVID‐19, 17 July 2020 https://doi.org/10.1111/bcp.14476
85. RAHMAN et al., Comparison of Viral Clearance between Ivermectin with Doxycycline and Hydroxychloroquine with Azithromycin in COVID-19 Patients J. Bangladesh Coll. Phys. Surg. 38, 5-9, doi:10.3329/jbcps.v38i0 (Peer Reviewed) - “Conclusion: It appears Ivermectin and Doxycycline is safeand effective combination drug therapy in COVID- 19infected patients but need further extensive study to find out the scope of application on other groups of patients”. https://www.banglajol.info/index.php/JBCPS/article/view/47514
86. RAJTER et al., 2020. Use of Ivermectin is Associated with Lower Mortality in Hospitalized Patients with COVID-19 (ICON study) Chest, doi:10.1016/j.chest.2020.10.009 (Peer Reviewed) death, ?https://pubmed.ncbi.nlm.nih.gov/33065103/ ” Ivermectin treatment was associated with lower mortality during treatment of COVID-19, especially in patients with severe pulmonary involvement”. Retrospective 280 hospitalized patients showing lower mortality with ivermectin (13.3% vs 24.5%), propensity matched odds ratio OR 0.47 (0.22-0.99), p=0.045.
87. RAJTER et al.,2020. Use of Ivermectin is Associated with Lower Mortality in Hospitalized Patients in COVID19, medRxiv. 2020 https://doi.org/10.1101/2020.06.06.20124461
88. REZAI et al., 2020. IRCT20111224008507N3 (Preprint) Effectiveness of Ivermectin in the Treatment of Coronavirus Infection in Patients admitted to Educational Hospitals of Mazandaran in 2020 RCT in Iran showing shorter time to clinical recovery with Ivermectin. Results are from: (1) https://c19study.com/rezai.html
89. RIZZO, E., 2020. Ivermectin, antiviral properties and COVID-19: a possible new mechanism of action, Naunyn-Schmiedeberg’s Arch Pharmacol 393, 1153–1156 (2020). https://doi.org/10.1007/s00210-020-01902-5
90. SMIT, M, Ochomo E, et al., 2018. Safety and mosquitocidal efficacy of high-dose ivermectin when co-administered with dihydroartemisinin-piperaquine in Kenyan adults with uncomplicated malaria (IVERMAL): a randomised, double-blind, placebo-controlled trial, The Lancet Infectious Diseases, March 27, 2018, ISSN: 1473-3099, Vol: 18, Issue: 6, Page: 615-626 DOI: https://doi.org/10.1016/S1473-3099(18)30163-4
91. TAY, M. Y., Fraser, J. E., et al. 2013. Nuclear localization of dengue virus (DENV) 1-4 non-structural protein 5; protection against all 4 DENV serotypes by the inhibitor Ivermectin. Antiviral research, 99(3), 301–306. https://doi.org/10.1016/j.antiviral.2013.06.002
92. VACINAS. “Pfizer Pays $2.3 Billion to Settle Marketing Case.” (September 2009). The New York Times. Accessed July 25, 2016.
93. VACINAS. https://www.nytimes.com/2020/10/20/health/covid-vaccines-fda-trump.html
94. VARGHESE, F. S., Kaukinen, P., et al. 2016. Discovery of berberine, abamectin and ivermectin as antivirals against chikungunya and other alphaviruses. Antiviral research, 126, 117–124. https://doi.org/10.1016/j.antiviral.2015.12.012
95. WAGSTAFF, et al. 2012. Ivermectin is a specific inhibitor of importin alpha/beta-mediated nuclear import able to inhibit replication of HIV-1 and dengue virus, Biochem. J., 443 (3) (2012), pp. 851-856 Citado en: https://doi.org/10.1016/j.antiviral.2020.104787
96. YANG et al., 2020. The broad spectrum antiviral ivermectin targets the host nuclear transport importin α/β1 heterodimer, Antiviral Research, Volume 177, May 2020, 104760. https://doi.org/10.1016/j.antiviral.2020.104760
97. YANG, S., Atkinson, S. C., et al. 2020. The broad spectrum antiviral ivermectin targets the host nuclear transport importin α/β1 heterodimer. Antiviral research, 177, 104760. https://doi.org/10.1016/j.antiviral.2020.104760
98 . Hydroxychloroquine and Azithromycin.
April 1, 2020
99. Ivermectin Protects Nuclear Pore Complex (NPC).
March 29, 2020
100. Decreasing Ventilator Tidal Volume (TV) to Reduce Deaths.
May 4, 2000
101. Lopinavir-Ritonavir Not Successful.
May 7, 2020
102. Reduce TV on Ventilators for Patients with ARDS to Reduce Deaths.
July 22, 2004
April 10, 2020
99. ACEI and ARBs in the Patients with Heart Disease.
May 1, 2020
100. Multiple Treatment Considerations.
April 28, 2020
101. Rethinking ACEI and ARBS.
April 23, 2020
102. Simple Ventilator & Breathing Terms for Students Using Ventilators.
2008
103. Prone Positioning of Patients Saves Lives.
June 6, 2013
104. Prone Positioning of Patients.
April 8, 2020
105. Azithromycin and Zika Virus.
December 13, 2016
106. Chloroquine Reduces Interleukins.
November 29, 2005
July 18, 2021
108. Pfizer UK Yellow Card Adverse Event Data.
June 30, 2021
May 6, 2021
110. https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/what-gene-therapy
May 11, 2016
112. . Patients are NOT Receiving Adequate Informed Consent.
December 4, 2020
113. Evidence of Long Term Durable Natural Immunity to SARS-CoV-2 Following Infection.
July 20, 2021
114. SARS-CoV-2 Bayesian Analysis Concludes SARS-CoV-2 Was NOT Natural BUT Laboratory Developed.
January 29, 2021
115. Harm Caused by Excluding Family Visitation.
January 11, 2021
116. Multiple Benefits to Patients with Family Visitation.
September 15, 2020
117. Supportive Evidence for Family ICU Visitation.
November 2011
118. Impact of Family Presence in the Healthcare Setting.
Spring 2014
119. Let Families into Intensive Care Units (ICUs).
March 6, 2016
120. The Family Needs of Intensive Care Unit (ICU) Patients.
March 25, 2019
121. Hospital Systems Have Chosen the Fear for Us.
October 21, 2020
122. Aerosol Transmission of SARS-CoV-2?
August 7, 2020
August 25, 2021
August 25, 2021
125. The Importance of the Innate T-Cell Immune System in Children.
July 26, 2021
126. Antibodies to Spike Protein Can Cause Severe Acute (sudden) Lung Disease.
February 21, 2019
127. SARS-CoV-1 Vaccine Leads to Lung Disease.
April 20, 2012
128. Pfizer, Moderna & Janssen Drug Vaccines Cause More Harm than Good.
August 25, 2021
August 6, 2021
130. Delta Variant (B.1.617.2) Surging in Israel In Spite of Pfizer Two Dose Vaccinations.
July 31, 2021
131. German Outbreak of Alpha (B.1.1.7) Variant Following Pfizer Two Dose Vaccinations.
August 2021
July 2005
133. Pfizer Vaccine Shown to Reduce Innate T-Cell Response.
October 22, 2020
July 28, 2020
September 2021
May 6, 2021
January 26, 1972
October 23, 2020
August 16, 2021
140. Tess Lawrie to Boris Johnson. A letter to Mr. Boris Johnson from UK scientist Dr. Tess Lawrie calling on him to start saving lives with Ivermectin. Health Rising 2021. Forums. Health News
[141] Database of all ivermectin COVID-19 studies. 55 studies, 21 peer reviewed, 35 with results comparing treatment and control groups. Submit updates/corrections below. FLCCC provides treatment recommendations.
[142] Ivermectin is effective for COVID-19: real-time meta analysis of 35 studies -
https://ivmmeta.com/
100% of the 35 studies to date report positive effects. Early treatment is more successful, with an estimated reduction of 84% in the effect measured using a random effects meta-analysis, RR 0.16 [0.08-0.33]. Prophylactic use also shows.
[143] Chamie-Quintero et al., Preprint, doi:10.2139/ssrn.3765018 (Preprint) Sharp Reductions in COVID-19 Case Fatalities and Excess Deaths in Peru in Close Time Conjunction, State-By-State, with Ivermectin Treatments Analysis of ivermectin usage within states in Peru showing sharp reductions in COVID-19 deaths corresponding to the usage of ivermectin treatment. https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3765018 21-1-2021— “ These sharp major reductions in COVID-19 mortality following IVM treatment thus occurred in each of Peru’s states, with such especially sharp reductions in close time conjunction with IVM treatments in each of the nine states of operation MOT.”
[144] Heidary et al. , Ivermectin: a systematic review from antiviral effects to COVID-19 complementary regimen The Journal of Antibiotics, 73, 593–602, doi:10.1038/s41429-020-0336-z (Review) (Peer Reviewed) https://www.nature.com/articles/s41429-020-0336-z Review of the antimicrobial, antiviral, and anti-cancer properties of ivermectin. Antiviral effects have been reported for Zika, dengue, yellow fever, West Nile, Hendra, Newcastle, Venezuelan equine encephalitis, chikungunya, Semliki For.. “In vivo studies of animal models revealed a broad range of antiviral effects of ivermectin, however, clinical trials are necessary to appraise the potential efficacy of ivermectin in clinical setting”.
[145] Mody et al., Communications Biology, doi:10.1038/s42003-020-01577-x (Peer Reviewed) (In Vitro) in vitro Identification of 3-chymotrypsin like protease (3CLPro) inhibitors as potential anti-SARS-CoV-2 agents Computational molecular modeling screening and in vitro analysis for inhibitory effects on SARS-CoV-2 specific 3CLpro enzyme, showing that ivermectin blocked more than 85% of 3CLpro activity of SARS-CoV-2. Antiviral activity of ivermectin. https://www.nature.com/articles/s42003-020-01577-x “In summary, these molecules [inclui a ivermectina] could be useful to develop highly specific therapeutically viable drugs to inhibit the SARS-CoV-2 replication either alone or in combination with drugs specific for other SARS-CoV-2 viral targets.”
[146] HILL, A, 2021. Prof Andrew Hill: See Whipple T. Ivermectin: Tests show cheap drug may reduce Covid-19 death toll. The TImes 2021 Jan 4. https://www.thetimes.co.uk/article/ivermectin-tests-show-cheap-drug-may-...
[147] HILL et al., Research Square, doi:10.21203/rs.3.rs-148845/v1 (Preprint) (meta analysis) meta-analysis Meta-analysis of randomized trials of ivermectin to treat SARS-CoV-2 infection Meta analysis of 18 ivermectin RCTs with 2,282 patients showing faster viral clearance (dose and duration dependent), improved clinical recovery, and lower hospitalization and mortality. In six RCTs of moderate or severe infection, there .. ” This meta-analysis investigated ivermectin in 18 randomized clinical trials (2282 patients) identified through systematic searches of PUBMED, EMBASE, MedRxiv and trial registries. Ivermectin was associated with reduced inflammatory markers (C-Reactive Protein, d-dimer and ferritin) and faster viral clearance by PCR. Viral clearance was treatment dose- and duration-dependent. In six randomized trials of moderate or severe infection, there was a 75% reduction in mortality (Relative Risk=0.25 [95%CI 0.12-0.52]; p=0.0002); 14/650 (2.1%) deaths on ivermectin; 57/597 (9.5%) deaths in controls) with favorable clinical recovery and reduced hospitalization”. https://www.researchsquare.com/article/rs-148845/v1
[148] MARIK, Paul 2020. The I-MASK+ protocol will revolutionize the treatment of COVID-19. The FLCCC Alliance press conference in Houston, Texas, Dec 4, 2020 , Front Line COVID-19 Critical Care Alliance.
[149] US Senate to the NIH. https://www.hsgac.senate.gov/imo/media/doc/40-317_Comm.%20Homeland%20Sec...
[150] Raad et al., ChiCTR2000033627 (Preprint) In vivo use of ivermectin (IVR) for treatment for corona virus infected patients (COVID-19): a randomized controlled Trial https://c19ivermectin.com/raad.html RCT in Lebanon showing significantly lower viral load at day 3, and lower hospitalization.
[151] Asghar et al., NCT04392713 (Preprint) Efficacy of Ivermectin in COVID-19 https://clinicaltrials.gov/ct2/show/NCT04392713 RCT with 103 patients in Pakistan comparing ivermectin and CQ, showing significantly lower PCR+ at day 7 with ivermectin.
[152] KORY et al., Frontiers in Pharmacology, doi:10.3389/fphar.2021.643369 (Review) (Peer Reviewed) review Review of the Emerging Evidence Demonstrating the Efficacy of Ivermectin in the Prophylaxis and Treatment of COVID-19 https://osf.io/wx3zn/?fbclid=IwAR1D8zI_SzOtaFAOG840QYFfdtvjcNxtd38-ej-hG_uj_RBIbkKYwCHnUbQ Meta analysis of ivermectin clinical studies and natural experiments where ivermectin has been widely used, showing efficacy of ivermectin in prophylaxis and treatment of COVID-19.” Although it is now standard practice for trials data from pré-print servers to immediately influence therapeutic practices during the pandemic, given the controversial therapeutics adopted as a result of this practice, the FLCCC argues that it is imperative that our major national and international health care agencies devote the necessary resources to more quickly validate these studies and confirm the major, positive epidemiological impacts that have been recorded when ivermectin is widely distributed among populations with a high incidence of COVID 19 infections”.
[153] Okumus et al., NCT04646109 (Preprint) Ivermectin for Severe COVID-. Management https://clinicaltrials.gov/ct2/show/NCT04646109
[154] Ravikirti et al., medRxiv, doi:10.1101/2021.01.05.21249310 (Preprint) death, ?88.7%, p=0.12 Ivermectin as a potential treatment for mild to moderate COVID-19: A double blind randomized placebo-controlled Trial https://www.medrxiv.org/content/10.1101/2021.01.05.21249310v1 - “Conclusion There was no difference in the primary outcome i.e. negative RT-PCR status on day 6 of admission with the use of ivermectin. However, a significantly higher proportion of patients were discharged alive from the hospital when they received ivermectin”.
[155] BABALOLA et al., medRxiv, doi:10.1101/2021.01.05.21249131 (Preprint) viral+, ? Ivermectin shows clinical benefits in mild to moderate Covid19 disease: A randomised controlled double blind dose response study in Lagos https://www.medrxiv.org/content/10.1101/2021.01.05.21249131v1 “Conclusions 12 mg IV regime may have superior efficacy. IV should be considered for use in clinical management of SARS-Cov-2, and may find applications in community prophylaxis in high-risk áreas”. “CONCLUSIONS: Ivermectin use is associated with reduced duration of febrile illness in COVID-19 in outpatient setting, thus potentially saving precious lives, reducing direct load on healthcare facilities and preventing high cost of management in a community setting”.
[156] HUSSAIN et al.2020. International Journal of Molecular and Immuno Oncology, doi:10.25259/IJMIO_30_2020 (Peer Reviewed) Outcome of ivermectin and doxycycline in cancer patients with COVID-19: A positive experience in Bangladesh - “The World Health Organization estimated that the period of this viral shedding is up to 9 days and 20 days for the patients with mild symptoms and for those who are hospitalized, respectively.[1] We report data of eight SARSCoV-2-infected cancer patients who were treated with ivermectin and doxycycline combination and recovered in 6 days only. In addition, our patients remained non-infectious to other people in the hospital as the successive two PCR tests were negative”. https://covid19.cdmx.gob.mx/storage/app/media/Articulos/OutcomeofivermectinanddoxycyclineincancerpatientswithCOVID-19_ApositiveexperienceinBangladesh.pdf Small case study of ivermectin + doxycycline with 8 cancer patients, with all patients becoming PCR- by day 6 when tested again.
[157] CHACCOUR et al.,2020. EClinicalMedicine, doi:10.1016/j.eclinm.2020.100720 (preprint 12/7) (Peer Reviewed) The effect of early treatment with ivermectin on viral load, symptoms and humoral response in patients with non-severe COVID-19: A pilot, double-blind, placebo-controlled, randomized clinical trial - https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(20)30464-8/fulltext Tiny RCT for early treatment of mild COVID-19 in low risk patients, with 12 400mcg/kg single dose ivermectin patients and 12 control patients, showing significantly faster viral load reduction and symptom improvement with ivermectin. “Among patients with non-severe COVID-19 and no risk factors for severe disease receiving a single 400 mcg/kg dose of ivermectin within 72 h of fever or cough onset there was no difference in the proportion of PCR positives. There was however a marked reduction of self-reported anosmia/hyposmia, a reduction of cough and a tendency to lower viral loads and lower IgG titers which warrants assessment in larger trials”.
[158] AHMED et al.,2020. International Journal of Infectious Diseases, doi:10.1016/j.ijid.2020.11.191 (Peer Reviewed) A five day course of ivermectin for the treatment of COVID-19 may reduce the duration of illness” - There were no severe adverse drug events recorded in the study. A 5-day course of ivermectin was found to be safe and effective in treating adult patients with mild COVID-19. Larger trials will be needed to confirm these preliminary findings”.
[159] CHAMIE, J. (News) The effect of using ivermectin to control COVID-19 in Chiapas https://c19ivermectin.com/chamie.html After starting to distribute ivermectin in drug kits in July, the Mexican state of Chiapas has seen a dramatic divergence from other states with much lower mortality [1, 2].
[160] ALONSO et al., (Preprint) -
https://c19ivermectin.com/
Observational study in Argentina showing significantly lower mortality in the 60 days after adopting ivermectin compared to the 60 days before,
[161] KORY, P, 2021. VÍDEO - Médico Pierre Kory em entrevista sobre a ivermectina e COV-19 – junho 2021:
https://d.tube/#!/v/fernando17/QmY6kGuVT7ae8dCeMiXKMufapTB85s23Fq26wSEsPy2LB4
_ _ __